Cybin Inc. to Present at Two Major Conferences
Ticker: HELP · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: conference-participation, biotech, mental-health
TL;DR
Cybin CEO Drysdale speaking at H.C. Wainwright & Cantor Fitzgerald conferences next month. Big pharma attention incoming?
AI Summary
On June 19, 2024, Cybin Inc. announced its participation in the H.C. Wainwright BioConnect Conference on June 25, 2024, and the 2024 Cantor Fitzgerald Virtual Mental Health Conference on July 10, 2024. CEO Doug Drysdale is scheduled to present at both events, highlighting Cybin's progress in psychedelic therapeutics.
Why It Matters
Participation in these conferences allows Cybin to showcase its advancements in mental health treatments to investors and industry professionals, potentially increasing visibility and interest in the company's pipeline.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and speculative field of psychedelic therapeutics, which carries inherent risks related to clinical trial success, regulatory approval, and market adoption.
Key Players & Entities
- Cybin Inc. (company) — Registrant
- Doug Drysdale (person) — CEO of Cybin Inc.
- H.C. Wainwright BioConnect Conference (company) — Event presenter
- Cantor Fitzgerald Virtual Mental Health Conference (company) — Event presenter
- June 25, 2024 (date) — H.C. Wainwright Conference date
- July 10, 2024 (date) — Cantor Fitzgerald Conference date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is to report a news release dated June 19, 2024, announcing Cybin Inc.'s participation in upcoming conferences.
Which conferences will Cybin Inc. be participating in?
Cybin Inc. will be participating in the H.C. Wainwright BioConnect Conference on June 25, 2024, and the 2024 Cantor Fitzgerald Virtual Mental Health Conference on July 10, 2024.
Who will be presenting on behalf of Cybin Inc. at these conferences?
Doug Drysdale, Chief Executive Officer of Cybin Inc., will be presenting at both conferences.
What is Cybin Inc.'s primary business focus?
Cybin Inc. is focused on pharmaceutical preparations, specifically in the development of psychedelic therapeutics for mental health conditions.
When was this report filed with the SEC?
This report was filed with the SEC on June 20, 2024.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-06-20 09:51:18
Filing Documents
- cybininc-form6xk06x19x2024.htm (6-K) — 11KB
- a06-19x2024hcwneuroperspec.htm (EX-99.1) — 8KB
- image_0.jpg (GRAPHIC) — 25KB
- 0001628280-24-029028.txt ( ) — 54KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date June 20, 2024 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated June 19, 2024